Phio Pharmaceuticals Corp.
For the period ended Sep 11, 2025. Filed Jul 30, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Sep 11, 2025 · Filed Jul 30, 2025
Use the contents to explore the available documents and sections.
Contents
Key Data
When approving the share increase under the 2020 Plan, the Board considered the burn rate with respect to the equity awards granted by the Company, as well as the Company’s overhang. The burn rate is equal to the total number of equity awards the Company granted in a fiscal year divided by the weighted average Common Stock outstanding during the year. The Company’s three-year average burn rate as of the Record Date was approximately 4%.
Overhang is equal to the total number of equity awards outstanding plus the total number of shares available for grant under the Company’s equity plans, divided by the sum of the total Common Stock outstanding, the number of equity awards outstanding and the total number of shares available for grant under the Company’s equity plans. The Company’s overhang as of the Record Date was 5%. If the share increase under the 2020 Plan is approved, the Company’s overhang would increase to 15%.
The following table sets forth information regarding outstanding equity awards and shares available for future equity awards under the 2020 Plan as of the Record Date (without giving effect to approval of the share increase under the 2020 Plan):
| Total shares underlying outstanding stock options | 1,126 |
|---|---|
| Weighted average exercise price of outstanding stock options | $1,206.29 |
| Weighted average remaining contractual life of outstanding stock options (in years) | 8.24 |
| Total shares underlying outstanding unvested RSUs | 71,000 |
| Total shares remaining available for issuance | 891 |
| Total shares of Common Stock outstanding | 4,798,154 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.